Which category of targeted drugs does Inavolisib belong to?

Inavolisib (Inavolisib) is a PI3K (phosphatidylinositol 3-kinase) inhibitor and is a targeted therapy drug mainly used to treat breast cancer and other tumor types with PIK3CA mutations. The PI3K pathway plays a key role in cell proliferation, survival and metabolism. In some cancers, PIK3CA gene mutations can lead to abnormal activation of the PI3K pathway and promote tumor growth and metastasis. Inaliset exerts its therapeutic effect by inhibiting the activity of the PI3K pathway and preventing the proliferation of tumor cells.

PI3K inhibitor drugs, such as inalise, are an important category of targeted therapies. These drugs are different from traditional chemotherapy drugs. Targeted drugs can specifically target certain molecules or signaling pathways in cancer cells to intervene, thereby reducing damage to normal cells and improving the accuracy and effectiveness of treatment. Compared with chemotherapy drugs, PI3K inhibitors have relatively few side effects and can precisely attack the root cause of cancer at the molecular level - the genetic mutations of cancer cells.

The mechanism of action of inarisep is to selectively inhibit the α isoform of PI3K, preventing downstream signaling in the PI3K pathway, and ultimately inhibiting the growth and spread of tumors. During the treatment process, inaliset is often used in combination with other drugs, especially with palbociclib and fulvestrant, to form a comprehensive treatment plan to enhance the efficacy and improve the patient's survival.

In general, as aPI3K inhibitor, inaliset is an important member of targeted drugs and has shown good clinical prospects in the treatment of tumors related to PIK3CA mutations. Through precise targeted therapy, it provides new treatment options for cancer patients, especially in the treatment of endocrine-resistant breast cancer patients, showing unique advantages.

Keyword tags:

Inalise, PIK3CA mutation, PI3K inhibitor, breast cancer, targeted therapy, clinical monitoring

Reference materials:https://en.wikipedia.org/wiki/Inavolisib